MIRA
INFORM REPORT
|
Report Date : |
17.01.2008 |
IDENTIFICATION
DETAILS
|
Name : |
NENZA PHARMACEUTICALS PVT LIMITED |
|
|
|
|
Registered Office : |
33-A, Industrial Estate, Hayatabad, Peshawar |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
1997 |
|
|
|
|
Com. Reg. No.: |
0038042 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture
& Marketing of Pharmaceutical Products. |
RATING &
COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Business Name
NENZA PHARMACEUTICALS (PVT) LIMITED
Full Address
Registered
Address & Factory
33-A, Industrial Estate, Hayatabad, Peshawar, Pakistan
Tel 92 (91) 5812769, 5891264
Fax 92 (91) 5822635
Email nenza@brain.net.pk
Short Description Of
Business
Nature of Business Manufacture & Marketing of Pharmaceutical
Products
Year
Established 1997
Registration
# 0038042
Branches
Street # 3, Abshar Colony,
Kababian, Warsak Road,
Peshawar, Pakistan
Auditors
Mushtaq Akbar & Co.
(Chartered
Accountants)
Suit No. 1, Block-A, 2nd Floor, Cantonment Plaza, Saddar Road, Peshawar, Pakistan
Legal Status
Subject Company was established as a Private Limited Company in 1997
Authorized Capital
Rs.
20,000,000/- divided into 200,000 shares of Rs. 100/- each
Issued & Paid up Capital
Rs.
19,934,000/- divided into 199,340 shares of Rs. 100/- each
Details of Chief Executive/ Directors
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Naveed Gul Mr. Nadeem Niazi Mr. Muhammad Jamshed Mr. Faisal Nazir |
Pakistani Pakistani Pakistani Pakistani |
Street # 3, Abshar Colony, Kababian, Warsak Road, Peshawar, Street # 3, Abshar Colony, Kababian, Warsak Road, Peshawar, Street # 3, Abshar Colony, Kababian, Warsak Road, Peshawar, Street # 3, Abshar Colony, Kababian, Warsak Road, Peshawar, |
Business Business Business Business |
Chief Executive Director Director Director |
Shareholders
Names
Mr. Naveed Gul
Mr. Nadeem Niazi
Mr. Muhammad Jamshed
Mr. Faisal Nazir
Mrs. Rubina Nadeem
Mrs. Rukhsana Naveed
Mrs. Zahida Parveen
Associates
SUBSIDIARY
None
ASSOCIATED COMPANIES
Narman
International, Pakistan
Products / Services
Manufacture & marketing of Pharmaceutical Products by its brand names of ADIX, ANTIFOCINE, COOLANT-S, DEYEAST, DROTA, FEN-100, FLOTIN, MASTAL, NENCID, NENDONE, NENFLEX, NENGESIC-CF, NENSEC, NENSIF, NENXIME, NENZOLE, RICLOR, SECAZOLE, STIMULAX, TRAUMALAX
Number of Employees
70
Trade Suppliers (Foreign)
Subject mainly imports Pharmaceutical Raw Materials from
some international companies belongs to China, India & Germany
Annual Production Volume
The capacity and production of the company’s plant is indeterminable as it involves varying processes of manufacture
Annual Sales Volume
|
Year |
In Pak Rupees |
|
2006 |
50,000,000/- (Estimated) |
Authorized Distributors
Mainly in Peshawar, Quetta & Afghanistan
Bankers
Habib Bank Limited, New Bara Market, Peshawar, Pakistan.
(Mortgage obtained PKR 6,955,000/-)
Memberships
- Sarhad Chamber of Commerce & Industry.(LCCI)
Foreign Exchange Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 62.50 |
|
UK Pound |
1 |
Rs. 122.30 |
|
Euro |
1 |
Rs. 92.40 |
Comments
Subject Company was established in 1997 and is engaged in manufacture & marketing of Pharmaceutical Products. Overall reputation is satisfactory. Trade relations are reported as fair. The Company can be considered for normal business dealings at usual trade terms & conditions.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)